Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | -564.00 | -60.50K | -55.11K | -564.00 |
EBITDA | -13.20M | -7.00M | -13.32M | -19.46M | -10.93M |
Net Income | -13.20M | -7.00M | -12.73M | -19.42M | -10.86M |
Balance Sheet | |||||
Total Assets | 5.04M | 4.74M | 5.73M | 7.47M | 5.49M |
Cash, Cash Equivalents and Short-Term Investments | 3.75M | 2.83M | 4.00M | 6.06M | 4.40M |
Total Debt | 0.00 | 0.00 | 207.38K | 256.96K | 0.00 |
Total Liabilities | 975.86K | 653.08K | 2.46M | 3.97M | 1.51M |
Stockholders Equity | 4.07M | 4.08M | 3.28M | 3.51M | 3.99M |
Cash Flow | |||||
Free Cash Flow | -6.92M | 0.00 | -11.19M | -12.01M | -7.63M |
Operating Cash Flow | -6.92M | -6.81M | -11.19M | -11.95M | -7.63M |
Investing Cash Flow | 0.00 | 1.50M | 0.00 | -34.02K | -350.00K |
Financing Cash Flow | 7.85M | 4.13M | 9.13M | 13.64M | 5.61M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $7.59B | 0.18 | -63.14% | 2.16% | 16.34% | 0.64% | |
32 Underperform | $8.11M | ― | -217.01% | ― | ― | 45.99% | |
31 Underperform | $8.36M | ― | 270.52% | ― | ― | 85.97% | |
24 Underperform | $8.92M | <0.01 | 13.29% | ― | ― | -261.69% | |
15 Underperform | $4.48M | ― | -206.26% | ― | ― | 75.68% |
On March 20, 2025, Adial Pharmaceuticals entered into an employment agreement with Tony Goodman to serve as the Chief Operating Officer starting April 1, 2025, with a base salary of $300,000 and potential bonuses. Goodman has been acting as COO since January 2024 under a Master Services Agreement, which will terminate with the new employment agreement, providing stability and continuity in leadership for the company.
On February 25, 2025, Adial Pharmaceuticals announced a positive response from the FDA regarding its in vitro bridging strategy for AD04, following a submission made on November 19, 2024. This agreement with the FDA marks a significant regulatory milestone, allowing Adial to proceed with manufacturing clinical supplies for the upcoming Phase 3 clinical program in 2025, advancing AD04 toward potential market approval as a treatment for addiction.